1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
  • 1.2.2 Teduglutide
  • 1.2.3 Linaclotide
  • 1.2.4 Others
• 1.3 Market by Application
  • 1.3.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Share by Application: 2020 VS 2026
  • 1.3.2 Hospital Pharmacies
  • 1.3.3 Retail Pharmacies
  • 1.3.4 Online Pharmacies
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Perspective (2015-2026)
• 2.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Growth Trends by Regions
  • 2.2.1 Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Peptide Based Gastrointestinal Disorders Therapeutics Historic Market Share by Regions (2015-2020)
  • 2.2.3 Peptide Based Gastrointestinal Disorders Therapeutics Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Peptide Based Gastrointestinal Disorders Therapeutics Players by Market Size
  • 3.1.1 Global Top Peptide Based Gastrointestinal Disorders Therapeutics Players by Revenue (2015-2020)
  • 3.1.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Revenue Market Share by Players (2015-2020)
• 3.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Peptide Based Gastrointestinal Disorders Therapeutics Revenue
• 3.4 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Concentration Ratio
  • 3.4.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Peptide Based Gastrointestinal Disorders Therapeutics Revenue in 2019
• 3.5 Key Players Peptide Based Gastrointestinal Disorders Therapeutics Area Served
• 3.6 Key Players Peptide Based Gastrointestinal Disorders Therapeutics Product Solution and Service
• 3.7 Date of Enter into Peptide Based Gastrointestinal Disorders Therapeutics Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Peptide Based Gastrointestinal Disorders Therapeutics Breakdown Data by Type (2015-2026)

• 4.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Historic Market Size by Type (2015-2020)
• 4.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Forecasted Market Size by Type (2021-2026)

5 Peptide Based Gastrointestinal Disorders Therapeutics Breakdown Data by Application (2015-2026)

• 5.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Historic Market Size by Application (2015-2020)
• 5.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2015-2026)
• 6.2 North America Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Type (2015-2020)
• 6.3 North America Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Application (2015-2020)
• 6.4 North America Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Country (2015-2020)
  • 6.4.1 United States
  • 6.4.2 Canada

7 Europe

• 7.1 Europe Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2015-2026)
• 7.2 Europe Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Type (2015-2020)
• 7.3 Europe Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Application (2015-2020)
• 7.4 Europe Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Country (2015-2020)
  • 7.4.1 Germany
  • 7.4.2 France
  • 7.4.3 U.K.
  • 7.4.4 Italy
  • 7.4.5 Russia
  • 7.4.6 Nordic
  • 7.4.7 Rest of Europe

8 China

• 8.1 China Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2015-2026)
• 8.2 China Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Type (2015-2020)
• 8.3 China Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Application (2015-2020)
• 8.4 China Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Region (2015-2020)
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 Southeast Asia
  • 8.4.5 India
  • 8.4.6 Australia
  • 8.4.7 Rest of Asia-Pacific

9 Japan

• 9.1 Japan Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2015-2026)
• 9.2 Japan Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Type (2015-2020)
• 9.3 Japan Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Application (2015-2020)
• 9.4 Japan Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Country (2015-2020)
  • 9.4.1 Mexico
  • 9.4.2 Brazil

10 Southeast Asia

• 10.1 Southeast Asia Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2015-2026)
• 10.2 Southeast Asia Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Type (2015-2020)
• 10.3 Southeast Asia Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Application (2015-2020)
• 10.4 Southeast Asia Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Country (2015-2020)
  • 10.4.1 Turkey
  • 10.4.2 Saudi Arabia
  • 10.4.3 UAE
  • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

• 11.1 Takeda
  • 11.1.1 Takeda Company Details
  • 11.1.2 Takeda Business Overview
  • 11.1.3 Takeda Peptide Based Gastrointestinal Disorders Therapeutics Introduction
  • 11.1.4 Takeda Revenue in Peptide Based Gastrointestinal Disorders Therapeutics Business (2015-2020))
  • 11.1.5 Takeda Recent Development
• 11.2 Ironwood Pharmaceuticals
  • 11.2.1 Ironwood Pharmaceuticals Company Details
  • 11.2.2 Ironwood Pharmaceuticals Business Overview
  • 11.2.3 Ironwood Pharmaceuticals Peptide Based Gastrointestinal Disorders Therapeutics Introduction
  • 11.2.4 Ironwood Pharmaceuticals Revenue in Peptide Based Gastrointestinal Disorders Therapeutics Business (2015-2020)
  • 11.2.5 Ironwood Pharmaceuticals Recent Development
• 11.3 Astellas Pharma
  • 11.3.1 Astellas Pharma Company Details
  • 11.3.2 Astellas Pharma Business Overview
  • 11.3.3 Astellas Pharma Peptide Based Gastrointestinal Disorders Therapeutics Introduction
  • 11.3.4 Astellas Pharma Revenue in Peptide Based Gastrointestinal Disorders Therapeutics Business (2015-2020)
  • 11.3.5 Astellas Pharma Recent Development
• 11.4 Allergan
  • 11.4.1 Allergan Company Details
  • 11.4.2 Allergan Business Overview
  • 11.4.3 Allergan Peptide Based Gastrointestinal Disorders Therapeutics Introduction
  • 11.4.4 Allergan Revenue in Peptide Based Gastrointestinal Disorders Therapeutics Business (2015-2020)
  • 11.4.5 Allergan Recent Development
• 11.5 Takeda Pharmaceutical
  • 11.5.1 Takeda Pharmaceutical Company Details
  • 11.5.2 Takeda Pharmaceutical Business Overview
  • 11.5.3 Takeda Pharmaceutical Peptide Based Gastrointestinal Disorders Therapeutics Introduction
  • 11.5.4 Takeda Pharmaceutical Revenue in Peptide Based Gastrointestinal Disorders Therapeutics Business (2015-2020)
  • 11.5.5 Takeda Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer

Global Peptide Based Gastrointestinal Disorders Therapeutics Scope and Market Size
Peptide Based Gastrointestinal Disorders Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Peptide Based Gastrointestinal Disorders Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Market segment by Type, the product can be split into
Teduglutide
Linaclotide
Others

Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Based on regional and country-level analysis, the Peptide Based Gastrointestinal Disorders Therapeutics market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Peptide Based Gastrointestinal Disorders Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Takeda
Ironwood Pharmaceuticals
Astellas Pharma
Allergan
Takeda Pharmaceutical
...